<DOC>
	<DOCNO>NCT01916278</DOCNO>
	<brief_summary>A 12-month , randomised , evaluator-blinded , comparative , multicentre study safety efficacy lip injection Emervel Lips Lidocaine Juvéderm Volbella Lidocaine .</brief_summary>
	<brief_title>Safety Efficacy Study Lip Injections With Emervel Lips Lidocaine Juvéderm Volbella With Lidocaine</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Female male subject age 18 65 year . Subjects intention undergo lip augmentation treatment ( vermilion mucosa , applicable , vermilion border ) . Subjects LFGS score 0 ( thin ) , 1 ( thin ) 2 ( moderately thick ) ( score may differ upper low lip ) , lip appearance judge treat investigator suitable optimal correction ( ≥ 1 grade improvement LFGS per lip ) maximum 1.5 mL study product per lip . Subjects sign informed consent . Concomitant anticoagulant therapy therapy inhibitor platelet aggregation ( e.g . aspirin nonsteroidal antiinflammatory drug [ NSAIDs ] ) , Omega3 vitamin E within 10 day study treatment , history bleeding disorder . Prior surgery tattoo upper low lip lip line . Presence abnormal lip structure , scar lump severe lip asymmetry , judge investigator . Tendency form keloid , hypertrophic scar heal disorder . Previous tissue augment therapy lip area ( include lip , oral commissure , nasolabial fold , marionette perioral line ) HA collagen filler , laser treatment , within 12 month study entry . Permanent implant treatment nonHA noncollagen filler lip area ( include lip , oral commissure , nasolabial fold , marionette perioral line ) . Previous toxin treatment low orbital rim within 9 month study entry . History herpes labialis outbreak within 4 week study entry 4 outbreak 12 month study entry . Active skin disease , inflammation related condition , infection , psoriasis herpes zoster near area treat . History angioedema . Known hypersensitivity HA , lidocaine amidetype anaesthetic history severe multiple allergy anaphylactic shock Cancerous precancerous lesion area treat . Immunosuppressive therapy , chemotherapy , treatment biologics systemic corticosteroid within 3 month study treatment . Any medical condition opinion investigator would make subject unsuitable inclusion ( e.g . chronic , relapse hereditary disease may affect general condition may require frequent medical treatment ) . Pregnancy breast feed . Participation clinical study within 30 day inclusion . Other condition prevent subject enter study investigator 's opinion , e.g . subject likely avoid facial cosmetic treatment level low orbital rim chin , subject anticipate unreliable incapable understand comply study assessment unrealistic expectation treatment result . Study site staff close relative study site staff employee sponsor company close relative employee sponsor company . Close relative define parent , child , sibling spouse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>